Please assess the completion status of the following clinical trial:

Trial Title: Preventing pAIn With NMDA Antagonists - Steroids in Thoracoscopic lObectomy Procedures (PAIN-STOP) Pilot Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* 18-75 years of age,~* Planned elective VATS pulmonary lobectomy,~* Provide written informed consent to participate.~Exclusion Criteria:~* Current pain on the same side of the chest of moderate to severe intensity (\>3/10 in 0-10 numerical rating scale (NRS) - where 0=no pain, 10=maximum pain),~* Known intracranial mass or cerebral aneurysm or raised intraocular pressure,~* Severe renal impairment (creatinine clearance based GFR of \<30ml/min),~* Allergies to one or more of the study medications,~* Steroid treatment \> 10mg/day of Prednisolone or its equivalent for \> 3 weeks within the last 3 months,~* History of schizophrenia or bipolar disorder,~* History of drug addiction (prescription or non-prescription drug addiction diagnosed by a physician, excluding alcohol),~* Current diagnosis of Cushing's syndrome,~* Pregnancy,~* Previous participation in the PAIN-STOP trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- NMDA active + Steroid placebo (Type: EXPERIMENTAL): NMDA active: ketamine (0.5 mg/kg IV bolus pre-incision and 0.1 mg/kg/hr infusion postoperatively up to 24 hours) and oral memantine (5 mg BID \[first week\]; 10 mg BID \[following three weeks\]).~Steroid placebo: two doses of normal saline; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day.
- Steroid active + NMDA placebo (Type: EXPERIMENTAL): NMDA placebo: normal saline (IV bolus pre-incision and infusion postoperatively up to 24 hours) and oral matching placebo to memantine (one capsule BID \[first week\]; one capsule BID \[following three weeks\]).~Steroid active: two doses of dexamethasone; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day.
- NMDA active + Steroid active (Type: EXPERIMENTAL): NMDA active: ketamine (0.5 mg/kg IV bolus pre-incision and 0.1 mg/kg/hr infusion postoperatively up to 24 hours) and oral memantine (5 mg BID \[first week\]; 10 mg BID \[following three weeks\]).~Steroid active: two doses of dexamethasone; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day.
- NMDA placebo + Steroid placebo (Type: PLACEBO_COMPARATOR): NMDA placebo: normal saline (IV bolus pre-incision and infusion postoperatively up to 24 hours) and oral matching placebo to memantine (one capsule BID \[first week\]; one capsule BID \[following three weeks\]).~Steroid placebo: two doses of normal saline; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day.

Based on this trial design, predict the completion outcome and termination type (if applicable).